Latest Clinical Trials News

Recce Pharmaceuticals is progressing its Phase 3 clinical trial of RECCE 327, a novel synthetic antibiotic targeting multidrug-resistant infections, with interim data from Indonesia supporting registration plans across ASEAN by 2026.

Nexalis Therapeutics has initiated dosing in its Phase 1 trial of IRX-616a, a novel cannabidiol inhalation treatment targeting panic disorder. The trial aims to evaluate safety and pharmacokinetics, with dose escalation decisions expected soon.

Imricor Medical Systems has filed a Form 10 registration with the U.S. SEC, marking its transition to a U.S. reporting company amid ongoing FDA clearances and clinical trials. This move signals a significant step in its early commercialisation of MRI-guided cardiac ablation technology.

Immutep Limited has successfully completed the single ascending dose phase of its IMP761 trial, showing promising safety and immunosuppressive effects in healthy volunteers. The biotech’s novel LAG-3 agonist could reshape autoimmune disease treatment.

Imugene Limited has launched a $20 million equity raising comprising a $12 million placement and an $8 million Share Purchase Plan, alongside issuing options, convertible notes, and warrants to support its azer-cel clinical program.

dorsaVi has secured significant commercial and clinical milestones with new elite sports and European clinical partnerships, showcasing its advanced real-time AI sensor technology.

Clarity Pharmaceuticals has unveiled compelling Phase II trial results showing its Cu-SAR-bisPSMA PET imaging agent significantly improves detection of prostate cancer recurrence over the current standard. The data, presented at the 2026 European Association of Urology Congress and accepted by European Urology journal, mark a key milestone ahead of regulatory submissions.

Neurotech International has opened the first clinical site for its pivotal Phase 3 trial of NTI164, targeting core symptoms of Autism Spectrum Disorder in children. This milestone marks a key step toward potential regulatory approval and commercialisation.

Argenica Therapeutics has secured a nearly $4 million R&D tax incentive rebate for FY25, strengthening its cash position as it prepares for a pivotal Phase 2b trial of its neuroprotective peptide ARG-007.

Resonance Health has received a $732,851 refund from the Australian Taxation Office, reflecting its FY2025 R&D tax incentive claim net of income tax payable. This cash inflow strengthens the company’s financial position ahead of its March quarterly report.

Arovella Therapeutics has secured TGA confirmation to advance its Phase 1 trial of ALA-101 in Australia via the efficient Clinical Trial Notification pathway, following FDA clearance in the US.

Percheron Therapeutics has announced a $2.2 million non-renounceable entitlement offer at a 20% discount, including free options, to fund the next phase of its lead oncology asset HMBD-002.